Amagma Therapeutics | January 19, 2022
Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform.
Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest.
The collaboration will allow Innovent to access novel, first-in-class molecules for inflammatory disorders with little to no existing treatment options. Amagma will secure clinical manufacturing for its lead programs and gain a proven regional partner with extensive expertise in protein engineering and manufacturing.
Under the terms of the agreement, Innovent will be responsible for the manufacture of the three programs through a Phase 2 study and, if Innovent exercises its option, research, development, and commercialization of each program in Greater China.
Amagma will continue to be responsible for global research and development prior to option exercise and ex-China research, development and commercialization thereafter.
Amagma is eligible to receive development, approval, and commercial milestones if Innovent exercises the options. Amagma may also receive royalties on net sales of any commercial products in the territory.
“This transaction highlights an innovative approach to securing manufacturing expertise in exchange for insights into novel disease biology from our SEIZMIC™ platform. Innovent has demonstrated themselves to be an excellent partner with robust capabilities and strong execution. We look forward to working with Innovent to potentially advance these novel therapies.”
Tillman Gerngross, Ph.D., Co-founder, Chairman, Amagma Therapeutics
About Amagma Therapeutics
Amagma Therapeutics is developing precision antibody therapeutics against inflammatory diseases which have proven to be intractable by other approaches. A number of these serious illnesses are driven by overactive extracellular proteases which can compromise organ function and fuel inflammation. The Company’s SEIZMIC proprietary discovery platform enables screening and development of highly selective antibodies that can inhibit dysfunctional enzyme activity. Amagma was founded in 2019 by serial entrepreneur scientists Leonard Zon and Tillman Gerngross. Amagma is based in Waltham, MA.
Read More
MEDICAL
Sesen Bio | December 02, 2020
Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the registration and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer ("NMIBC") and different sorts of cancer in MENA. Vicineum, a privately managed combination protein, is Sesen Bio's lead product competitor presently in the subsequent phase of a Phase 3 enrollment preliminary for the treatment of high-hazard, BCG-unresponsive NMIBC. In December 2019, the Company started the BLA submission for Vicineum to the FDA under Rolling Review.
Under the details of the understanding, Sesen Bio granted Hikma a exclusive license to register and commercialize Vicineum in all of the 19 MENA markets in a course of action foreseen to convey equivalent worth offer to the two players. Monetary terms of the arrangement are secret and incorporate a forthright installment to Sesen Bio, deals related achievement installments, and eminences on net deals in the locale for the term of the understanding. Sesen Bio holds full turn of events and commercialization rights for Vicineum for the treatment of NMIBC in the US and the remainder of the world barring Greater China and MENA.
Read More
MEDTECH
Ochre Bio | December 15, 2021
Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health.
“On our path to develop next-generation RNA medicines with the potential to improve the lives of patients in need of a liver transplant, we are grateful to have access to discarded donor livers, allowing us to develop therapeutics that are safe and effective when we enter the clinical evaluation stage,” said Jack O’Meara, CEO at Ochre Bio. “As we are progressing our preclinical evaluation, we are proud to support the great work of the British Liver Trust. We highly appreciate their effort in supporting patients, caregivers, and healthcare professionals on all aspects of liver health including prevention and early detection, and we look forward to a close partnership as we execute on our unified goal.”
The British Liver Trust is the UK's leading liver health charity, recognised by Her Majesty's Revenue and Customs and the Charity Commissions in England, Wales and Scotland, is working to improve liver health and supporting patients affected by liver disease or cancer. Reaching millions of people each year, the British Liver Trust raises awareness for the risk factors of liver disease, provides advice to help people improving their liver health and submits the most updated information to patients.
“In the UK, one out of six patients dies while waiting for a liver transplant. Ochre Bio’s research has the potential to improve these numbers and with that the chances of successful treatment for liver disease patients. We are really excited that Ochre Bio is supporting the aims of the British Liver Trust and we delighted to have this partnership with important shared goals,”
Pamela Healy OBE, Chief Executive of the British Liver Trust
About Ochre Bio
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer. We uncover new biological pathways by using advances in 'deep phenotyping', and then study our medicines in human livers kept alive on machines. In doing so, Ochre Bio ensures that the medicines we bring to the clinic are highly likely to successfully improve patient lives. Situated within the heart of Oxford’s biotech innovation hub, Ochre is built on over 15 years experience in liver genomics and bringing advanced therapies to market.
Read More